Differential Regulation of Lipoprotein Kinetics in Atorvastatin and Fenofibrate in Subjects With the Metabolic Syndrome

Gerald Watts, Hugh Barrett, June Ji, A.P. Serone, Dick Chan, Kevin Croft, F. Loehrer, A.G. Johnson

Research output: Contribution to journalArticle

183 Citations (Scopus)

Abstract

The metabolic syndrome is characterized by insulin resistance and abnormal apolipoprotein AI (apoAI) and apolipoprotein B-100 (apoB) metabolism that may collectively accelerate atherosclerosis. The effects of atorvastatin (40 mg/day) and micronised fenofibrate (200 mg/day) on the kinetics of apoAI and apoB were investigated in a controlled cross-over trial of 11 dyslipidemic men with the metabolic syndrome. ApoAI and apoB kinetics were studied following intravenous d(3)-leucine administration using gas-chromatography mass spectrometry with data analyzed by compartmental modeling. Compared with placebo, atorvastatin significantly decreased (P < 0.001) plasma concentrations of cholesterol, triglyceride, LDL cholesterol, VLDL apoB, intermediate-density lipoprotein (IDL) apoll, and LDL apoll. Fenofibrate significantly decreased (P < 0.001) plasma triglyceride and VLDL apoB and elevated HDL2 cholesterol (P < 0.001), HDL3 cholesterol (P < 0.01), apoAI (P = 0.01), and apoAII (P < 0.001) concentrations, but it did not significantly alter LDL cholesterol. Atorvastatin significantly increased (P < 0.002) the fractional catabolic rate (FCR) of VLDL apoB, EDL apoB, and LDL apoB but did not affect the production of apoll in any lipoprotein fraction or in the turnover of apoAI. Fenofibrate significantly increased (P < 0.01) the FCR of VLDL, IDL, and LDL apoB but did not affect the production of VLDL apoB. Relative to placebo and atorvastatin, fenofibrate significantly increased the production (P < 0.001) and FCR (P = 0.016) of apoAI. Both agents significantly lowered plasma triglycerides and apoCIII concentrations, but only atorvastatin significantly lowered (P < 0.001) plasma cholesteryl ester transfer protein activity. Neither treatment altered insulin resistance. In conclusion, these differential effects of atorvastatin and fenofibrate on apoAI and apoll kinetics support the use of combination therapy for optimally regulating dyslipoproteinemia in the metabolic syndrome.
Original languageEnglish
Pages (from-to)803-811
JournalDiabetes
Volume52
Issue number3
DOIs
Publication statusPublished - 2003

Fingerprint Dive into the research topics of 'Differential Regulation of Lipoprotein Kinetics in Atorvastatin and Fenofibrate in Subjects With the Metabolic Syndrome'. Together they form a unique fingerprint.

Cite this